FDA Offers More Flexibility on Residual Solvents in Generic Drug Applications
Executive Summary
FDA's Office of Generic Drugs has taken a more flexible approach in implementing the U.S. Pharmacopeia's General Chapter <467> on residual solvents
You may also be interested in...
In Final Guidance On Residual Solvents, FDA Allows Control, Not Just Testing, Verification
Agency accepts industry comments on testing issue, but document may still contain hurdles for approval of some generic drugs.
Generic Firms Object To Policy Behind Residual Solvents Deficiency Letters
FDA's Office of Generic Drugs has interpreted a new pharmacopoeial standard for residual solvents in an unexpectedly rigorous manner, rejecting dozens of applications and raising the ire of generic drug manufacturers
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”